Literature DB >> 6255785

Studies with aprindine.

D P Zipes, V Elharrar, R F Gilmour, J J Heger, E N Prystowsky.   

Abstract

Aprindine is a very effective antiarrhythmic agent with a narrow therapeutic-toxic ratio. It has been used successfully in treating patients who have both supraventricular and ventricular tachyarrhythmias. Aprindine slows conduction in all cardiac fibers and suppresses digitalis-induced after-depolarizations. Voltage-clamp studies indicate that aprindine, in higher doses, suppresses the slow inward current in frog atria. In the dog subjected to coronary artery occlusion, aprindine may be arrhythmogenic, antiarrhythmic, or have no effect on the development of arrhythmias, depending on the temporal relationship between time of administration and time of occlusion.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6255785     DOI: 10.1016/0002-8703(80)90213-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

Review 1.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

Review 2.  Is there an ideal antiarrhythmic drug? A review--with particular reference to class I antiarrhythmic agents.

Authors:  K A Muhiddin; P Turner
Journal:  Postgrad Med J       Date:  1985-08       Impact factor: 2.401

3.  Dose-dependent pharmacokinetics of aprindine in healthy volunteers.

Authors:  T Kobari; T Itoh; T Hirakawa; H Namekawa; T Suzuki; T Satoh; N Iida; F Ohtsu; H Hayakawa
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 4.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

5.  Effects on transmembrane action potential, slow inward current and force of contraction in ventricular cardiac muscle of BRL 31660, a new antiarrhythmic drug with class I and class IV activity.

Authors:  R Brückner; W Schmitz; H Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-03       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.